Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-27T10:49:02.713Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparación del comienzo del efecto de los antidepresivos: consideraciones pragmáticas sobre los métodos y los puntos finales

Published online by Cambridge University Press:  12 May 2020

D. Hackett
D. Hackett*
Affiliation:
Wyeth-Ayerst Research, European CR&D, Le Wilson II, 80 ave du Président Wilson, Puteaux, 92031Paris La Défense Cedex, Francia
Get access

Resumen

No existe una definición aceptada de lo que constituye el comienzo del efecto antidepresivo, y esto limita la evaluación de la validez de muchos informes comparativos. Para clarificar la naturaleza de los métodos de comparación necesarios, se propone separar conceptualmente dos preguntas de investigación distintas: 1) ¿cuándo comienzan a actuar clínicamente los medicamentos antidepresivos? y 2) ¿producen todos los medicamentos antidepresivos el alivio de los síntomas en los pacientes dentro de un período de tiempo similar? Se puede hacer también una distinción metodológica en función de si el comienzo del efecto de un antidepresivo se evalúa como si tuviera una cualidad absoluta (“rápido”) o como si fuera rápido en relación con otros tratamientos (“más rápido”). La elección de objetivo ayudará a definir el enfoque metodológico, la aplicabilidad de los resultados y las dificultades a las que es preciso dirigirse. Describir un antidepresivo como una sustancia que muestra un comienzo “rápido” o “más rápido” de la respuesta requiere que se trate de definir en cualquier caso (en términos que se puedan generalizar) la naturaleza de la comparación (¿más rápido que qué?), la naturaleza del efecto (¿más rápido para hacer qué?) y la población en la que este efecto se puede esperar (más rápido en quién?). Se revisan algunos detalles de los enfoques metodológicos y se hacen propuestas para diseños de estudio.

Keywords

metodología de los ensayos clínicosantidepresivoscomienzo de la acción
Type
Research Article
Information
European Psychiatry (Ed. Española) , Volume 5 , Issue 7 , October 1998 , pp. 420 - 428
Copyright
Copyright © European Psychiatric Association 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Hackett D. Comparing onset of effect of antidepressants: pragmatic considerations on methods and end-points. Eur Psychiatry 1998; 13: 117-123.

References

Bibliografía

Amsterdam, JDCase, WGCsanalosi, ESinger, MRickels, K, A double blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression. Pharmacopsychiatry 1986; 19: 115-9.CrossRefGoogle ScholarPubMed
Angst, JDelini Stula, AStabl, MStassen, HH.Is a cut off score a suitable measure of treatment outcome in short term trials in depression? A methodological meta analysis. Hum Psychopharmacol 1993; 8: 311-17.CrossRefGoogle Scholar
Artigas, FRomero, Lde Montigny, CBlier, P.Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-83.Google ScholarPubMed
Benkert, OGrunder, GWetzel, HHackett, D, A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996; 30: 441-51.CrossRefGoogle ScholarPubMed
Blier, PBergeron, Rde Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333-8.CrossRefGoogle ScholarPubMed
Brink, CWDunbar, GCBehagel, HA, A controlled clinical trial of mianserin and placebo in the treatment of depression in general practice. Tijdschr Ther Geneesm Onderz 1984; 9: 513-17.Google Scholar
Carman, JSAhdieh, HWyatt, KEWarga, EPanagides, J, A controlled study of mianserin in moderately to severely depressed outpatients. Psychopharmacol Bull 1991; 27: 135-9.Google ScholarPubMed
Cohn, JB, Wilcox. Paroxetine in major depression: a double blind trial with imipramine and placebo. CS J Clin Psychiatry 1992; 53 suppl 2: 52-6.Google ScholarPubMed
Derivan, AEntsuah, ARKikta, D, Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995; 31: 439-47.Google ScholarPubMed
Dunbar, GCCohn, JBFabre, LFFeighner, JPFieve, RR et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991; 159: 394-8.CrossRefGoogle Scholar
Edwards, JGGoldie, A. Placebo controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report. Br J Clin Pharmacol 1983; 15 suppl 2: 239S-48S.CrossRefGoogle ScholarPubMed
Fabre, LFCrismon, L. Efficacy of fluoxetine in outpatients with major depression. Ther Res Clin Exp 1985; 37: 115-23.Google Scholar
Feighner, JPMeredith, CHFrost, NR et al. A double blind comparison of alprazolam vs. imipramine and placebo in the treatment of major depressive disorder. Acta Psychiatr Scand 1983; 68: 223-33.CrossRefGoogle ScholarPubMed
Feighner, JPAden, GCFabre, LFRickels, KSmith, WT, Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983; 249: 3057-64.CrossRefGoogle ScholarPubMed
Feighner, JPMeredith, CHStem, WCHendrickson, GMiller, LL, A double blind study of bupropion and placebo in depression. Am J Psychiatry 1984; 141: 525-9.Google ScholarPubMed
Feighner, JP. A review of controlled studies of adinazolam mesylate in patients with major depressive disorder. Psychopharmacol Bull 1986; 22: 186-91.Google ScholarPubMed
Feighner, JPBoyer, P. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. WF J Clin Psychiatry 1992; 53 suppl 2: 44-7.Google ScholarPubMed
Feighner, JPCohn, JBFabre, LFJFieve, RR, Mendels J et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1983; 28: 71-9.CrossRefGoogle Scholar
Georgia, EH. Double blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients. J Clin Psychiatry 1984; 45. 43-6.Google ScholarPubMed
Gisselmann, A. Activité et acceptabilité de l’indalpine en double aveugle contre placebo. Encephale 1984; 10: 231-4.Google Scholar
Guelfi, JDWhite, CHackett, DGuichoux, JYMagni, G, Effectiveness of venlafaxine in patients hospitalised for major depression and melancholia. J Clin Psychiatry 1995; 56: 450-8.Google Scholar
Hicks, FRobins, EMurphy, GE, Comparison of adinazolam, amitriptyline, and placebo in the treatment of melancholic depression. Psychiatry Res 1988; 23: 221-7.CrossRefGoogle ScholarPubMed
Jansen, WSiegfried, K. Nomifensine in geriatrie inpatients: a placebo controlled study. J Clin Psychiatry 1984; 45: 63-7.Google Scholar
Katz, MMKoslow, SHMaas, JW et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 17: 297–309.CrossRefGoogle ScholarPubMed
Katz, MMKoslow, SHMaas, JW et al. Identifying the specifie clinical actions of amitriptyline: interrelationships of behaviour, affect and plasma levels in depression. Psychol Med 1991; 21: 599–611.CrossRefGoogle Scholar
Katz, MMKoslow, SHFrazer, A, Onset of antidepressant activity: re-examining the structure of depression and multiple actions of drugs. Depress Anxiety 197; 4: 257-67.Google Scholar
Leber, P. Speed of onset. Psychopharmacol Bull 1995; 31: 37–40.Google ScholarPubMed
Merideth, CHFeighner, JP. The use of bupropion in hospitalized depressed patients. J Clin Psychiatry 1983; 44: 85-7.Google ScholarPubMed
Miller, SMNaylor, GJMurtagh, M, Winslow. A double blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatr Scand 1989; 350: 143-4.CrossRefGoogle Scholar
Montgomery, SA. Are 2-week trials sufficient to indicate efficacy? Psychopharmacol Bull 1995; 31: 41-4.Google ScholarPubMed
Perez, VGilaberte, IFaries, DÁlvarez, EArtigas, F.Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-7.CrossRefGoogle ScholarPubMed
Prien, RFBlaine, JDLevin, J, Antidepressant drug therapy: the role of new antidepressants. Hosp Community Psychiatry 1985; 36: 513-16.Google ScholarPubMed
Pitts, WMFann, WEHalaris, AE et al. Bupropion in depression: a tri center placebo controlled study. J Clin Psychiatry 1983; 44: 95–100.Google ScholarPubMed
Quitkin, FMMcGrath, PJRabkin, JG et al. Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991; 148: 197–203.Google ScholarPubMed
Quitkin, FMRabin, JGStewart, JW et al. Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 1991; 148: 193-6.Google ScholarPubMed
Quitkin, FMStewart, JWMcGrath, PJ et al. Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 1993; 150: 566-70.Google ScholarPubMed
Quitkin, FMMcGrath, PJStewart, JWTaylor, BPKlein, DF, Can the effects of antidepressants be observed in the First two weeks of treatment? Neuropsychopharmacol 1996; 15: 390-4.CrossRefGoogle ScholarPubMed
Reimherr, FWChouinard, GCohn, CK et al. Antidepressant efficacy of sertraline: a double blind, placebo and amitriptyline controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51 suppl 12: 18–27.Google ScholarPubMed
Rickels, KFeighner, JPSmith, WT, Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. Arch Gen Psychiatry 1985; 42: 134-41.CrossRefGoogle ScholarPubMed
Rickels, KChung, HRCsanalosi, IB et al. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987; 44: 862-6.CrossRefGoogle ScholarPubMed
Robinson, DSRickels, KFeighner, J et al. Clinical effects of the 5 HT(1A) partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 suppl 3: 67S–76S.CrossRefGoogle Scholar
Stassen, HHDelini-Stula, AAngst, A, Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127-35.CrossRefGoogle ScholarPubMed
Stassen, HHAngst, JDelini-Stula, A, Severity at baseline and onset of improvement in depression. Meta analysis of imipramine and moclobemide versus placebo. Eur Psychiatry 1994; 9: 129-36.Google Scholar
Weissman, MMPrusoff, BSholomskas, AJGreenwald, S, A double blind clinical trial of alprazolam, imipramine, or placebo in the depressed elderly. J Clin Psychopharmacol 1992; 12: 175-82.Google ScholarPubMed
Wernicke, JFDunlop, SRDomself, BEBosomworth, JCHumbert, M, Low-dose fluoxetine therapy for depression. Psychopharmacology Bull 1988; 24: 183-8.Google ScholarPubMed